Tumor growth rate determines the timing of optimal chronomodulated treatment schedules - Institut Camille Jordan Accéder directement au contenu
Article Dans Une Revue PLoS Computational Biology Année : 2010

Tumor growth rate determines the timing of optimal chronomodulated treatment schedules

Résumé

In host and cancer tissues, drug metabolism and susceptibility to drugs vary in a circadian (24 h) manner. In particular, the efficacy of a cell cycle specific (CCS) cytotoxic agent is affected by the daily modulation of cell cycle activity in the target tissues. Anti-cancer chronotherapy, in which treatments are administered at a particular time each day, aims at exploiting these biological rhythms to reduce toxicity and improve efficacy of the treatment. The circadian status, which is the timing of physiological and behavioral activity relative to daily environmental cues, largely determines the best timing of treatments. However, the influence of variations in tumor kinetics has not been considered in determining appropriate treatment schedules. We used a simple model for cell populations under chronomodulated treatment to identify which biological parameters are important for the successful design of a chronotherapy strategy. We show that the duration of the phase of the cell cycle targeted by the treatment and the cell proliferation rate are crucial in determining the best times to administer CCS drugs. Thus, optimal treatment times depend not only on the circadian status of the patient but also on the cell cycle kinetics of the tumor. Then, we developed a theoretical analysis of treatment outcome (TATO) to relate the circadian status and cell cycle kinetic parameters to the treatment outcomes. We show that the best and the worst CCS drug administration schedules are those with 24 h intervals, implying that 24 h chronomodulated treatments can be ineffective or even harmful if administered at wrong circadian times. We show that for certain tumors, administration times at intervals different from 24 h may reduce these risks without compromising overall efficacy.
Fichier principal
Vignette du fichier
bernard2010PLoSComputBiol.pdf (626.87 Ko) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte
Loading...

Dates et versions

hal-00470302 , version 1 (06-04-2010)

Identifiants

Citer

Samuel Bernard, Branka Cajavec Bernard, Francis Lévi, Hanspeter Herzel. Tumor growth rate determines the timing of optimal chronomodulated treatment schedules. PLoS Computational Biology, 2010, 6 (3), pp.e1000712. ⟨10.1371/journal.pcbi.1000712⟩. ⟨hal-00470302⟩
409 Consultations
162 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More